Medtech dealmaking is set to accelerate in 2026 following a year of contrasts in 2025, when transaction value surged to decade-high levels even as overall deal volume remained constrained. According to PwC’s newly released US Deals 2026 outlook for the medtech sector, the industry recorded $92.8 billion in announced deal value through November 30, 2025—the highest level in more than a decade—driven primarily by three mega-transactions. However, only 46 deals were announced during that period, reflecting the cautious environment facing acquirers amid regulatory shifts, macroeconomic pressure, and evolving investor expectations.
HotSpot Take:
When deal value hits decade highs, but volume stays flat, the market signals selectivity—acquirers pay premium multiples for proven innovation platforms, not speculative bets.
The report frames 2026 as an inflection point where strategic portfolio realignment, technology-driven acquisitions, and expanded private equity participation converge to create a more active and targeted M&A environment. Several major acquisitions announced in the second half of 2025 signal strengthening momentum as companies with demonstrated above-market growth trajectories attract intensifying buyer interest.
AI-Driven Analytics and Robotics Platforms Lead Acquisition Priorities
PwC identifies technology as a primary catalyst for 2026 transaction activity, with acquirers prioritizing targets that accelerate digital transformation capabilities. AI-driven analytics, robotics platforms, and connected-care ecosystems represent focal areas where buyers seek scalable digital infrastructure and measurable clinical or operational impact.
“Momentum is accelerating into 2026 as medtech companies deploy capital with greater precision, using acquisitions and divestitures to strengthen capabilities and position themselves for sustained long-term growth.” — James Woods, Principal, US Medtech Leader, PwC US
The emphasis on AI and automation reflects broader market dynamics documented in multiple industry analyses. Deloitte’s 2025 MedTech M&A trends report notes that companies are “rapidly adopting cutting-edge/proprietary technologies (e.g., wearables and connected care, Generative AI-based solutions)” as these capabilities transform the sector and improve patient outcomes. Similarly, EY’s Pulse of the MedTech Industry 2025 report highlights that “companies that combine innovation with advanced data and AI tools” are best positioned to prove their right to grow in an increasingly competitive landscape.
For surgical robotics specifically, the market trajectory remains robust. According to CB Insights analysis published in November 2025, surgical robots are “entering a new phase as AI and computer vision make them more precise and safer to use across a wide range of procedures.” The firm notes that large companies are responding through acquisitions and investments, with companies like Johnson & Johnson leading funding rounds and securing distribution rights for emerging robotics platforms.
Strategic Divestitures Create Acquisition Pipeline for Growth Segments
Corporate portfolio reshaping will accelerate as companies concentrate capital on differentiated technologies and high-growth procedural segments including sports medicine, cardiovascular, and neurostimulation. PwC anticipates that divestitures of non-core or subscale assets will continue creating a deeper pipeline of actionable opportunities for both strategic and private equity buyers.
This capital reallocation supports renewed investment in platform technologies, adjacency expansion, and data-enabled solutions. The pattern is already visible in recent major transactions. GE HealthCare’s pending $2.3 billion acquisition of Intelerad Medical Systems—announced in November 2025—exemplifies the strategic logic driving consolidation, combining hospital-based imaging equipment leadership with cloud-first enterprise imaging software to capture the rapidly growing outpatient market.
Among 2025’s most significant transactions, Abbott Laboratories‘ $23.5 billion acquisition of Exact Sciences Corporation topped the list, followed by Blackstone Inc.‘s $20.5 billion purchase of Hologic, Inc. and Waters Corporation‘s $17.5 billion acquisition of the Biosciences and Diagnostics Solutions Business from Becton Dickinson and Company. Additional notable deals included Stryker Corporation‘s acquisition of Inari Medical for $4.9 billion and Thermo Fisher Scientific’s purchase of Solventum’s Purification and Filtration Business for $4.0 billion.
Private Equity Expands Role Through Structured Capital Solutions
Sponsors are positioned to play an even larger role in 2026 deal formation, according to PwC. While traditional platform acquisitions will continue, structured capital solutions, particularly build-to-buy constructs, are expected to persist as medtech companies seek flexible financing to accelerate innovation and growth. Sponsors’ ability to underwrite complex value-creation plans will keep them competitive against strategic acquirers in high-growth segments.
The private equity thesis finds support in broader market analysis. A December 2025 report from MergersAndAcquisitions.net examining 24 months of healthcare and medtech transaction activity notes that “if you look beyond the billion-dollar transactions, you’ll see a very healthy middle market that never lost its underlying momentum.” The analysis emphasizes that middle-market businesses with strong clinical evidence, recurring revenue mechanics, and defensible intellectual property “fit squarely into the buy-and-build frameworks of private equity while also filling capability gaps for strategics under pressure to innovate faster.”
This dynamic is particularly evident in specialized segments. According to the report, high-growth categories such as structural heart, peripheral vascular intervention, neurovascular, and specialized diagnostics continue to trade at notable valuation premiums, while more mature categories have stabilized at historically sustainable ranges.
Regulatory Scrutiny and Geopolitical Factors Lengthen Deal Timelines
Policy shifts, regulatory reviews such as the U.S. Section 232 inquiry, and ongoing geopolitical and macroeconomic volatility will continue shaping deal execution throughout 2026. These factors are likely to lengthen diligence timelines, complicate cross-border supply-chain assessments, and heighten scrutiny of synergies, data flows, and manufacturing integration.
Buyer emphasis on operational resilience, compliance rigor, and diversified sourcing reflects lessons learned from recent supply chain disruptions and regulatory uncertainty. Investor activism is also reinforcing portfolio discipline, with management teams facing pressure to accelerate divestitures and redirect capital toward higher-growth, innovation-led segments. While activists have been less visible through new campaigns, their influence continues driving more frequent portfolio reviews and decisions to separate or streamline underperforming assets.
IPO Market Remains Selective Despite Improved Conditions
Although capital markets showed tentative signs of improvement, PwC’s expectations for 2026 remain measured. Select IPOs may advance for diagnostics and minimally invasive technology companies with clear commercial traction. However, investor selectivity will stay high. Many emerging innovators are likely to continue favoring M&A, structured partnerships, or strategic investment over public listings, reinforcing M&A as a central pathway to scale.
This assessment aligns with EY’s finding that while macroeconomic uncertainty and challenges persist, the medtech sector “is proving to be a safe harbor within the relatively underperforming broader health care industry, generating stronger results and building confidence for the quarters ahead.” EY notes that medtech stocks grew 18% from their lowest post-COVID value in October 2023 through 2024, significantly outperforming the overall S&P 500 Health Care index’s 9% growth during the same period.
AI and Minimally Invasive Technologies Reshape Clinical Delivery
The strategic rationale for increased M&A activity extends beyond financial engineering to fundamental innovation drivers reshaping healthcare delivery. Medtech companies face sustained demand from consistent procedure volumes, an aging population requiring more complex interventions, and accelerating adoption of minimally invasive approaches that reduce recovery times and improve patient outcomes.
Innovations enabling more personalized care, advances in minimally invasive treatment, and expansion of digital platforms are widening the opportunity set. AI applications in diagnostics represent a particularly dynamic area. Research highlighted in recent industry analyses shows AI algorithms achieving 94% accuracy in detecting lung nodules compared to 65% for human radiologists, and 90% sensitivity in detecting breast cancer with mass versus 78% for radiologists.
For cardiovascular technologies, AI-enabled diagnostic platforms are transforming cardiac monitoring by analyzing extended-duration data to identify anomalies as brief as four errant heartbeats among 1.5 million typically recorded in a two-week monitoring period. These capabilities address critical clinical needs while creating strategic value for acquirers seeking differentiated technology platforms.
Strong Procedure Volumes and Digital Adoption Support Growth Projections
Despite near-term challenges, medtech fundamentals remain strong. The global surgical robotics market—valued at $9.1 billion in 2024—is projected to reach $22.9 billion by 2035 according to industry forecasts, representing compound annual growth exceeding 8%. Within that market, specific segments like orthopedics and neurosurgery show particularly strong adoption trajectories as residents train on emerging platforms and healthcare systems expand robotic capabilities beyond traditional urology and gynecology applications.
The AI in medical imaging diagnostics market presents similar growth dynamics, with market size estimated at $4.5 billion in 2024 and projected to reach $14.3 billion by 2032. Regulatory agencies have introduced streamlined approval pathways specifically for AI-based diagnostic tools, accelerating time to market while partnerships between AI startups and major medical device manufacturers increase to combine imaging hardware with embedded AI capabilities.
These growth rates underscore why strategic acquirers and private equity sponsors view medtech as an attractive deployment opportunity for capital accumulated during recent years of limited buy-side activity and portfolio streamlining.
Execution Discipline and Strategic Alignment Drive Success
As PwC concludes, “measured, innovation-driven M&A will remain a critical lever for growth and competitive positioning” as policies, regulations, and capital markets continue evolving. Successful dealmakers will combine strategic foresight with execution discipline, balancing near-term prudence with long-term conviction in an increasingly complex global environment.
The most successful companies will move with precision: aligning strategy and capability, forging partnerships that scale innovation, and deploying M&A as a primary engine of long-term value creation. With medtech companies holding strong balance sheets and demonstrating fundamental performance despite macroeconomic headwinds, the sector enters 2026 positioned for a broader resurgence in deal activity that extends beyond mega-transactions to encompass targeted, capability-building acquisitions across the innovation spectrum.
– This original article was created with AI support.
